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The characterization of the in vitro metabolites of toad venom, which has been widely 
used as a traditional Chinese drug, Ch’an Su, has been completed.  Toad venom 
contains bufotoxin (such as marinobufotoxin; marinobufagin 3-suberoylarginine ester) 
and bufogenin (such as marinobufagin, bufalin) as the main cardiac steroids.  An in 
vitro experiment using the rat or human liver cytosolic fraction disclosed that 
marinobufotoxin produced marinobufagin, but not its 3-hemisuberate.  Marinobufagin 
was subjected to the enzyme reaction using the rat or human liver microsomal fraction 
together with NADPH and NAD, which produced 3-dehydromarinobufagin and 
3-epimarinobufagin.  Marinobufagin produced its 3-sulfate upon treatment with the 
rat or human liver cytosolic fraction and 3’-phosphoadenosine 5’-phosphosulfate.  
Bufalin was also subjected to the above enzyme reactions and showed almost the same 
results except for the result that the hydroxylation has occurred at 5β-position.  On the 
other hand, small amounts of marinobufagin 3-glucuronide were obtained only by 
treatment with the human liver microsomal fraction and uridine 
5’-diphosphoglucuronic acid.  The structures of these metabolites were confirmed using 
authentic samples regarding their high performance liquid chromatographic behavior 
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Digitalis glycosides, represented by digoxin and digitoxin having a five-member lactone 
ring at the 17β-position of the steroid (cardenolide), have been commonly used for the 
treatment of congestive heart failure and other cardiac diseases.  The metabolic fates 
of these glycosides have already been clarified (Volp and Lage, 1978; Gault et al., 1982; 
Ohta et al., 1984).  On the other hand, toad venom has also been widely used as a 
traditional Chinese drug, Ch’an Su, where the bufotoxin and bufogenin having a six- 
member lactone ring at the 17β-position of the steroid (bufadienolide) are the main 
cardiac steroids (Shimada et al., 1977).  The metabolic fate of bufogenin (such as 
bufalin and cinobufagin) has been studied, and the 3-epimer has been obtained via the 
3-dehydro compound (Tóma et al., 1987; Shimada et al., 1989; Zhang et al., 1990; Zhang 
et al., 1991; Shimizu and Morishita, 1996) together with the other hydroxylated 
compounds, but the position of the introduced hydroxy group still remains unclear 
(Tóma et al., 1991).  Furthermore, the metabolic pathway of bufotoxin (bufogenin 
3-suberoylarginine ester) and the phase II metabolites of bufogenin have not been 
clarified.  The metabolism of toad venom, especially bufotoxin, has been poorly 
investigated in spite of the historic age of Ch’an Su as shown above. 
  In this study, we have clarified the in vitro metabolites of the representative 
bufotoxin, marinobufotoxin (marinobufagin 3-suberoylariginine ester), together with its 
genin, marinobufagin (Shimada et al., 1977) (Fig. 1a).  In comparison, those of the 
representative bufogenin, bufalin, were also studied (Fig. 1b).  The structures of these 
metabolites were confirmed using authentic samples regarding their high performance 
liquid chromatographic behavior and/or liquid chromatography-mass spectrometry 





Animals and chemicals.  Wistar strain rats (male, 7weeks old) were obtained from 
Japan SLC (Hamamatsu, Japan).  3’-Phosphoadenosine 5’-phosphosulfate (PAPS) and 
uridine 5’-diphosphoglucuronic acid (UDPGA) were obtained from Sigma-Aldrich (St. 
Louis, MO, USA) and Nacalai Tesque (Kyoto, Japan), respectively.  Marinobufotoxin, 
marinobufagin 3-hemisuberate, marinobufagin, bufalin and telocinobufagin were 
obtained from the Japanese toad venom (Shimada et al., 1977).  3-Epibufalin and 
3-dehydrobufalin (bufalone) were donated by Dr. Kamano (Kanagawa University, 
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Yokohama, Japan).  Strata-X (60 mg, 3 mL) cartridges were obtained from Shimadzu 
GLC (Shimadzu), and successively conditioned with MeOH (2 mL) and H2O (2 mL), 
prior to use. 
 
Apparatus.  High performance liquid chromatography (HPLC) was carried out using a 
Waters 600s controller (Waters, Milford, MA, USA) equipped with a 616 pump and 486 
tunable absorbance detector (UV 300 nm)(Waters).  A Symmetry C18 column (5 μm; 150 
mm×4.6 mm i.d.) (Waters) was used at a flow rate of 1.0 mL/min at 40℃ unless 
otherwise stated.  An LC/MS system, which consisted of a Shimadzu LC-10AT 
chromatograph (Shimadzu) coupled with an API 2000 triple-stage quadrupole mass 
spectrometer (Applied Biosystems, Foster City, CA, USA), was operated with 
electrospray ionization (ESI) in the positive-ion mode.  A Symmetry C18 column (5 μm; 
150 mm×2.1 mm i.d.) (Waters) was used at a flow rate of 0.2 mL/min at 40℃.  The 
ionization conditions were as follows: declustering potential, 30 V; entrance potential, 
12 V; curtain gas, 20 psi; turbo gas temperature, 500℃; ion source gas 1, 70 psi; ion 
source gas 2, 80 psi; interface heater, on.  The 1H-NMR spectra were obtained using a 
JEOL JNM-EX270 (270 MHz) or -GSX500 (500 MHz) spectrometer.  CDCl3 and Me4Si 
were used as the solvent and the internal standard, respectively. 
 
Synthesis of authentic samples.  3-Epimarinobufagin and 3-dehydromarinobufagin 
were synthesized in our laboratories according to the known procedure (Pettit and 
Kamano, 1972).  1H-NMR (3-epimarinobufagin) δ (500 MHz): 0.78 (3H, s, H-18), 0.93 (3H, 
s, H-19), 3.52 (1H, s, H-15α), 4.03 (1H, brs, H-3β), 6.25 (1H, d, J=10.5 Hz, H-23), 7.77 (1H, dd, 
J=10.5, 3.0 Hz, H-22).  (3-dehydromarinobufagin) δ (270 MHz): 0.82 (3H, s, H-18), 1.04 (3H, s, 
H-19), 3.54 (1H, s, H-15α), 6.27 (1H, d, J=10.5 Hz, H-23), 7.77 (1H, dd, J=10.5, 3.0 Hz, H-22). 
The sulfates of bufogenin and its 3-epimer were synthesized in our laboratories 
according to the known procedure (Shimada et al., 1977). LC/ESI-MS [MeOH-5 mM 
HCO2NH4 (pH 5.0 adjusted with HCO2H) (2:3)] marinobufagin 3-sulfate, tR 15.1 min, 
m/z 481.2 [M+H]+, 3-epimarinobufagin 3-sulfate, tR 13.5 min, m/z 481.2 [M+H]+, bufalin 
3-sulfate, tR 14.7 min, m/z 467.1 [M+H]+.   
 
Enzyme sources.  The pooled human liver microsomal and cytosolic fractions were 
purchased from Xenotech LLC (Lenex, KS, USA).  Rat liver tissues were homogenized 
in three volumes of 0.25 M sucrose and the homogenate was centrifuged at 9,000g for 20 
min.  The supernatant was further centrifuged at 105,000g for 60 min. The 9,000g and 
105,000g supernatants were used as the rat liver S9 fraction and the rat liver cytosolic 
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fraction, respectively.  The precipitate obtained from the centrifugation at 105,000g 
was used as the rat liver microsomal fraction.  The protein concentration was 
measured by the method of Bradford using bovine serum albumin as the standard 
(Bradford, 1976). 
 
Enzymatic hydrolysis of marinobufotoxin.  Marinobufotoxin (up to 100 μM final 
concentration in the incubation medium, from a stock solution in methanol) was added 
to the assay mixture (total volume of 1.0 mL) containing 1 mg protein of the rat or 
human liver cytosolic fraction in Tris-HCl buffer (pH 7.4, 50 mM) containing EDTA (2 
mM).  The assay mixture was incubated at 37℃ for 3 h.  After the incubation, the 
reaction was terminated by the addition of ethyl acetate (2 mL).  After extraction with 
ethyl acetate, the ethyl acetate layer was washed with H2O and evaporated to dryness 
under a N2 gas stream.  The residue was dissolved in methanol (100 μL ) and subjected 
to HPLC.   
 
Analysis of phaseⅠmetabolites of bufogenin.  Marinobufagin or bufalin (up to 100 μM 
final concentration in the incubation medium, from a stock solution in methanol) was 
added to the assay mixture (total volume of 0.5 mL) containing 1 mg protein of the rat or 
human liver microsomal fraction in Tris-HCl buffer (pH 7.4, 50 mM) containing NAD 
and NADPH (each 100 μM).  The assay mixture was incubated at 37℃ for 3 h.  After 
the incubation, the reaction was terminated by the addition of ethyl acetate (2 ml).  
After extraction with ethyl acetate, the ethyl acetate layer was washed with H2O and 
evaporated to dryness under a N2 gas stream.  The residue was dissolved in methanol 
(50 μL ) and subjected to HPLC. 
 
Sulfation assay.  Marinobufagin, 3-epimarinobufagin or bufalin (up to 50 μM final 
concentration in the incubation medium, from a stock solution in methanol) was added 
to the assay mixture (total volume of 0.5 mL) containing 0.5 mg protein of the rat or 
human liver cytosolic fraction in Tris-HCl buffer (pH 7.4, 50 mM) containing 
1,4-dithiothreitol (DTT, 50 μM), MgCl2 (5 mM) and PAPS (149 μM). The assay mixture 
was incubated at 37℃ for 2 h.  After the incubation, the reaction was terminated by 
heating for 5 min.  After centrifugation at 1,500g for 10 min, the supernatant was 
passed through a Strata-X cartridge.  After washing with H2O (2 mL) and ethyl acetate 
(2 mL), the conjugate was eluted with methanol (2 mL).  The methanol layer was 
evaporated to dryness under a N2 gas stream. The residue was dissolved in methanol 
(50 μL) and subjected to HPLC and/or LC/MS analysis. The authentic marinobufagin 
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3-sulfate (ca. 1 μg/tube) was quantitatively recovered (103%, n=2). 
 
Glucuronidation assay. Marinobufagin or 3-epimarinobufagin (up to 50 μM final 
concentration in the incubation medium, from a stock solution in methanol) was added 
to the assay mixture (total volume of 0.5 mL) containing 0.5 mg protein of the rat or 
human liver microsomal fraction in Tris-HCl buffer (pH 7.4, 50 mM) containing EDTA 
(1 μM), MgCl2 (5 mM), 0.05% Triton X-100 and UDPGA (4 mM).  The assay mixture 
was incubated at 37℃ for 2 h.  After the incubation, the reaction was terminated by 
heating for 5 min.  After centrifugation at 1,500g for 10 min, the supernatant was 
passed through a Strata-X cartridge.  After washing with H2O (2 mL) and ethyl acetate 
(2 mL), the conjugate was eluted with methanol (2 mL).  The methanol phase was 
evaporated to dryness under a N2 gas stream.  The residue was dissolved in methanol 
(50 μL) and subjected to the LC/MS analysis.  
 
 
RESULTS AND DISCUSSION 
 
The characterization of in vitro metabolites of toad venom, bufotoxin and bufogenin, has 
been done using HPLC and/or LC/MS.  The approximate conversion and recovery rates 
were calculated using an authentic sample regarding its UV absorption intensity at 300 
nm in HPLC/UV. 
 
Enzymatic hydrolysis of marinobufotoxin 
Marinobufotoxin was subjected to enzymatic hydrolysis using the rat or human liver 
cytosolic fraction.  The incubation mixture was extracted with ethyl acetate.  It was 
reported that marinobufagin and marinobufagin 3-hemisuberate was obtained from 
incubation mixture using hog pancreas lipase as an enzyme source by ethyl acetate 
extraction (Shimada et al., 1977).  About 10% of the marinobufotoxin produced 
marinobufagin, which was confirmed using an authentic sample regarding its HPLC 
chromatographic behavior [MeOH-0.5% AcONa (pH 5.0 adjusted with AcOH)(5:4), 
marinobufagin (tR 5.8 min), marinobufotoxin (tR 6.8 min); MeCN-0.5% AcONa (pH 5.0 
adjusted with AcOH)(2:3), marinobufagin (tR 5.6 min)], but marinobufagin 
3-hemisuberate has not been obtained [MeOH-0.5% AcONa (pH 5.0 adjusted with 
AcOH)(5:3), tR 9.0 min]. Even if the incubation time was reduced to ten min, 
marinobufagin 3-hemisuberate has not been obtained. The treatment of 
marinobufotoxin with the rat liver S9 fraction or microsomal fraction gave almost the 
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same results. These data showed that the enzyme reacted at the ester (-COOR) group 
rather than at the acid amide (-CONH-) group.   
 
Analysis of phaseⅠmetabolites of bufogenin 
Marinobufagin was subjected to an enzymatic reaction using the rat liver microsomal 
fraction in the presence of NAD and NADPH.  The residue obtained from the 
incubation mixture was subjected to HPLC using MeCN-H2O (1:2) as the mobile phase. 
3-Dehydromarinobufagin (tR 8.4 min) and 3-epimarinobufagin (tR 5.1 min) were 
confirmed using authentic samples regarding their chromatographic behavior together 
with the substrate (tR 11.7 min).  These were also confirmed by inclusion 
chromatography containing γ-cyclodextrin (CD)[MeOH-H2O (1:1) containing γ-CD (4 
mM); 3-epimarinobufagin (tR 5.6 min), 3-dehydromarinobufagin (tR 6.3 min), 
marinobufagin (tR 7.2 min)] (Fig. 2a).  The treatment of marinobufagin with the human 
liver microsomal fraction gave almost the same result.  The treatment of 
3-dehydromarinobufagin with the rat liver microsomal fraction in the presence of NAD 
and NADPH as described above gave not only 3-epimarinobufagin (ca. 20%) but also 
marinobufagin (ca. 12%).   
The representative bufogenin, bufalin, was also subjected to the reaction using the 
rat or human liver microsomal fraction to produce the 3-epimer together with bufalone 
[HPLC, Chromolith Performance RP-18e (100 x 4.6 mm i.d.; Merck, Darmstadt, 
Germany), MeOH-H2O (12:13); 3-epibufalin (tR 14.0 min), bufalone (tR 11.5 min), bufalin 
(tR 12.6 min)].  These data are compatible with our previous results using the rat liver 
homogenate in the presence of NADPH and NAD (Shimada et al., 1989).  About 30% of 
bufalin produced the new metabolite, telocinobufagin (Fig. 1b), upon treatment with the 
human liver microsomal fraction in the presence of co-factors, which was confirmed 
using an authentic sample regarding its HPLC chromatographic behavior [MeOH-H2O 
(11:9) containing γ-CD (2 mM), tR 8.9 min; Chromolith Performance RP-18e, MeOH-H2O 
(12:13) tR 7.9 min (Fig. 2b); Develosil 60-5 (5 μm, 250 x 4.6 mm i.d.; Nomura, Seto, 
Japan), AcOEt-isopropanol (95:5), tR 7.1 min].  It was reported that digitoxigenin 
(cardenolide) having a five-member lactone ring instead of the six-member one 
(bufadienolide) was metabolized to the 5β-hydroxylated metabolite (periplogenin) upon 
treatment with the rabbit liver homogenate (Bulger and Stohs, 1973), which is 
compatible to the above results. On the other hand, about 1% of bufalin produced 
telocinobufagin upon treatment with the rat liver microsomal fraction in the presence of 
co-factors and the main metabolite was 3-epimer (about 90% from the substrate).  
These different data obtained from rat and human demonstrated the differences in 
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different species.  
All of the above data showed that bufogenin having the 3β-hydroxy-5β-structure is 
enzymatically metabolized to the inactive metabolite having the 3α-hydroxy-5β-structure (Nambara 
et al., 1972) together with hydroxylation such as at 5β-position to give telocinobufagin. 
 
Sulfation assay.  Marinobufagin or 3-epimarinobufagin was treated with the rat or 
human liver cytosolic fraction together with PAPS.  After the incubation, the reaction 
mixture was passed through a Strata-X cartridge.  The substrate was washed out with 
ethyl acetate, and the conjugate was eluted with methanol.  The residue obtained from 
the incubation mixture was subjected to HPLC and LC/MS analysis.  Marinobufagin 
produced the 3-sulfate which was confirmed using an authentic sample regarding its 
HPLC chromatographic behavior [MeOH-5 mM HCO2NH4 (pH 5.0 adjusted with 
HCO2H) (2:3); tR 9.1 min] (Fig. 3a) and LC/ESI-MS analysis (Fig. 3b). However, the 
3-epimarinobufagin did not produce the respective 3-sulfate, which was confirmed using 
an authentic sample regarding its HPLC chromatographic behavior [MeOH-5 mM 
HCO2NH4 (pH 5.0 adjusted with HCO2H) (2:3); tR 7.1 min]. Bufalin was also subjected 
to the sulfation reaction to produce the sulfate, which was confirmed using an authentic 
sample regarding its chromatographic behavior [HPLC, MeOH-5 mM HCO2NH4 (pH 5.0 
adjusted with HCO2H) (2:3); tR 12.5 min] (Fig. 4a) and LC/ESI-MS analysis (Fig. 4b). 
  
Glucuronidation assay. Marinobufagin or 3-epimarinobufagin was treated with the rat 
or human liver microsomal fraction in the presence of UDPGA.  The residue obtained 
from the incubation mixture was subjected to an LC/ESI-MS analysis [MeOH-5 mM 
HCO2NH4 (pH 5.0 adjusted with HCO2H) (2:3), tR 9.2 min].  Marinobufagin produced 
small amounts of 3-glucuronide (less than 1 %) only by treatment with the human liver 
microsomal fraction (Fig. 5). The respective glucuronide has not been obtained under 
the other conditions. 
 
  All the above data suggested the following in vitro metabolic pathway of 
marinobufotoxin using the rat or human liver as an enzyme source as shown in Fig. 6.  
Marinobufotoxin was hydrolyzed to marinobufagin, which was transformed into the 
3-epimer possibly via the 3-dehydro compound.  Instead of glucuronidation, sulfation 
mainly occurred on marinobufagin to produce the marinobufagin 3-sulfate as the phase 
II metabolite of bufogenin.  The data showed that bufogenin is enzymatically metabolized 
to the biologically inactive sulfate (Shimada et al., 1985).  The representative bufogenin, 
bufalin, showed the similar metabolic pathway as marinobufagin.  But it is noteworthy 
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that telocinobufagin was obtained from bufalin upon treatment with the human and rat 
liver microsomal fraction in the presence of NADPH and NAD, which means 
hydroxylation occurred at 5β-position like the metabolic pathway of digitoxigenin 
(Bulger and Stohs, 1973). 
 
  Further experiments including the in vivo one are now in progress in our laboratories 
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Fig. 1.  Structures of bufotoxin and bufogenin 
        a) marinobufotoxin and related compounds  b) bufalin and related compounds 
 
Fig. 2.  HPLC chromatograms of phase I metabolites of bufogenin 
        Conditions; column, a) Symmetry C18 (5 μm; 150 mm x 4.6 mm i.d.) b)  
Chromolith Performance RP-18e (100 x 4.6 mm i.d.); detection,  
UV 300 nm; flow rate, 1 mL/min; solvent, a) MeOH-H2O (1:1) containing γ-CD 
(4 mM) b) MeOH-H2O (12:13); Substrate, a) marinobufagin b) bufalin;  
Enzyme source, a) rat liver microsomal fraction b) human liver microsomal 
fraction 
a) 1. 3-epimarinobufagin  2. 3-dehydromarinobufagin  3. marinobufagin 
b) 1. telocinobufagin  2.  bufalone   3.  bufalin   4. 3-epibufalin 
 
Fig. 3.  HPLC chromatogram (a) and LC/ESI-MS spectrum (b) of marinobufagin  
3-sulfate obtained from incubation mixture 
        Conditions; solvent, MeOH-5 mM HCOO2NH4 (pH 5.0 adjusted with  
HCOOH)(2:3)  a) column, Symmetry C18 (5 μm; 150 mm x 4.6 mm i.d.);  
detection, UV 300 nm; flow rate, 1 mL/min  b) column, Symmetry C18 (5 μm;  
150 mm x 2.1 mm i.d.); flow rate, 0.2 mL/min; tR 15.1 min 
Substrate, marinobufagin    Enzyme source, rat liver cytosolic fraction 
 
Fig. 4.  HPLC chromatogram (a) and LC/ESI-MS spectrum (b) of bufalin 3-sulfate  
obtained from incubation mixture 
Conditions; solvent, MeOH-5 mM HCOO2NH4 (pH 5.0 adjusted with  
HCOOH)(2:3)  a) column, Symmetry C18 (5 μm; 150 mm x 4.6 mm i.d.); 
detection, UV 300 nm; flow rate, 1 mL/min  b) column, Symmetry C18 (5 μm;  
150 mm x 2.1 mm i.d.); flow rate, 0.2 mL/min; tR 14.7 min 
Substrate, bufalin      Enzyme source, rat liver cytosolic fraction 
 
Fig. 5.  LC/ESI-MS spectrum of marinobufagin 3-glucuronide obtained from incubation  
        mixture 
Conditions; a) column, Symmetry C18 (5 μm; 150 mm x 2.1 mm i.d.); flow rate,  
0.2 mL/min; solvent, MeOH-5 mM HCOO2NH4 (pH 5.0 adjusted with  
HCOOH)(2:3); tR 9.2 min 




Fig. 6.  Proposed in vitro metabolic pathway of marinobufotoxin using rat or human 
 liver as an enzyme source 
              human liver only 















































Fig. 1. K. Shimada et al.
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Fig.4. K. Shimada et al.



















































Fig. 6. K. Shimada et al.
